Page last updated: 2024-11-04

fucose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-deoxy-D-galactopyranose : A deoxygalactose that is D-galactopyranose in which the hydroxy group at position 2 has been replaced by a hydrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Fucose: A six-member ring deoxysugar with the chemical formula C6H12O5. It lacks a hydroxyl group on the carbon at position 6 of the molecule. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-fucopyranose : The pyranose form of L-fucose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

fucose : Any deoxygalactose that is deoxygenated at the 6-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439804
CHEBI ID90759
SCHEMBL ID2303855
MeSH IDM0008873
PubMed CID17106
CHEMBL ID469449
CHEBI ID2181
CHEBI ID18287
SCHEMBL ID63943
MeSH IDM0008873

Synonyms (61)

Synonym
C02781
2-deoxy-d-galactose, 98%
deoxygalactose
2-deoxy-d-lyxohexose
(4r,5r,6r)-6-(hydroxymethyl)oxane-2,4,5-triol
AKOS015924826
NCGC00247029-02
2-deoxy-d-galactopyranose
25494-04-6
2-deoxy-galactopyranose
SCHEMBL2303855
mfcd00014649
CHEBI:90759
2-deoxy-d-lyxo-hexopyranose
2-deoxygalactopyranose
2-deoxy-d-galactose >99%
Q27162721
(4r,5r,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,4,5-triol
STARBLD0017288
DTXSID001312551
O_FULL_00100000000000_GS_657
fucose, l-
FUC ,
6-methyltetrahydropyran-2,3,4,5-tetraol
l-galactopyranose, 6-deoxy-
l-galactopyranose, 6-deoxy- (9ci)
l-galactomethylose
6-deoxy-l-galactopyranose
fucopyranose, l- (7ci)
l-fucose ,
87-96-7
C01019
6-deoxy-l-galactose
nsc-1219
fucose
l-fucopyranose
CHEBI:2181 ,
6-deoxy-l-galactopyranosel-fucopyranose
bdbm50242419
(-)-l-fucose
6-desoxygalactose
6-deoxy-l-beta-galactose
BMSE000036
(3s,4r,5s,6s)-6-methyloxane-2,3,4,5-tetrol
CHEMBL469449 ,
EPITOPE ID:152214
SCHEMBL63943
6-deoxy-galactopyranose
6-deoxy-galactose
6-deoxy-l-galactopyranoside
l-fuc
6-deoxy-galactopyranoside
fucopyranose
SHZGCJCMOBCMKK-DHVFOXMCSA-N
(3s,4r,5s,6s)-6-methyltetrahydro-2h-pyran-2,3,4,5-tetraol
Q409082
DTXSID501016770 ,
EN300-6732867
AKOS016844003
dtxcid201474965
chebi:18287

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" l-Fucose was without maternal toxicity or compound-related adverse effects on female reproduction and general growth and development of offspring at a maternal dietary level up to 1%, equivalent to a dose of 1655 mg/kg body weight (bw)/day."( Safety evaluation of the human-identical milk monosaccharide, l-fucose.
Baldwin, N; Choi, SS; Dakoulas, EW; Lynch, BS; Moore, C; Röhrig, CH; Roy, S; Thorsrud, BA, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" To understand how the degree of fucose modification affects the binding affinity of Fuc-BSA with hepatic lectins and serum MBP, a pharmacokinetic analysis was performed based on a physiological model."( Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells.
Hashida, M; Nishikawa, M; Opanasopit, P; Takakura, Y; Yamashita, F, 2001
)
0.31
" These results could be of great significance for PNA drug development, as they should allow modulation and fine-tuning of the pharmacokinetic profile of a drug lead."( Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers.
Dahl, O; Dolle, F; Hamzavi, R; Nielsen, PE; Tavitian, B,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"0 A resolution and, in combination with modeling, allowed a proposal to be made for the hydrogen-bond network in the binding site."( High affinity fucose binding of Pseudomonas aeruginosa lectin PA-IIL: 1.0 A resolution crystal structure of the complex combined with thermodynamics and computational chemistry approaches.
Gautier, C; Gilboa-Garber, N; Hofr, C; Imberty, A; Koca, J; Mitchell, EP; Perret, S; Pokorná, M; Sabin, C; Snajdrová, L; Wimmerová, M, 2005
)
0.33
"To understand the cytochemical properties of epididymal epithelial cells, the characteristics of glycoconjugates in the mouse epididymis were examined using the technique of lectin histochemistry combined with immunohistochemistry."( Cell- and region-specific expression of sugar chains in the mouse epididymal epithelium using lectin histochemistry combined with immunohistochemistry.
Fukui, T; Sawaguchi, A; Tajiri, S; Yoshinaga, K, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" This inhibitory effect of fucoidan on the absorption of heavy metals is apparently the consequence of the formation of metal complexes which are poorly absorbed from the intestinal lumen."( Influence of fucoidan on the intestinal absorption of iron, cobalt, manganese and zinc in rats.
Becker, G; Forth, W; Osterloh, K; Paskins-Hurlburt, AJ; Schäfer, S; Skoryna, SC; Tanaka, G, 1981
)
0.26
" But it is essentially characterised in the external glycosylation by a shift from sialylation to fucosylation depending on the transcriptional regulation of the corresponding glycosyltransferases, but also on coordinate changes in the activities of glycosyltransferases and of their regulatory proteins, in nucleotide-sugar bioavailability and in product degradation by oxidases."( Regulation of the intestinal glycoprotein glycosylation during postnatal development: role of hormonal and nutritional factors.
Biol-N'garagba, MC; Louisot, P,
)
0.13
" On the other hand, in-vivo evaluation showed maximum bioavailability and tumor targeting efficiency with minimum secondary drug distribution in various organs with formulated and anchored nano-carrier when compared with free drug."( Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics.
Garg, NK; Jain, A; Jain, S; Katare, OP; Kushwah, V; Nirbhavane, P; Sharma, R; Singh, B; Tyagi, RK, 2016
)
0.43
"Inhibiting component of therapy with (-)-epigallocatechin-3-gallate (EGCG) is low bioavailability of fresh tea polyphenols that outcome from insecurity under stomach related circumstances, insufficient transcellular transport."( Target challenging-cancer drug delivery to gastric cancer tissues with a fucose graft epigallocatechin-3-gallate-gold particles nanocomposite approach.
Feng, A; He, Y; Li, X; Yuan, X; Zheng, W; Zhou, G, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" This dosage schedule resulted in recurrent phosphate trapping predominantly in liver."( Consequences of recurrent phosphate trapping induced by repeated injections of 2-deoxy-D-galactose. Biochemical and morphological studies in rats.
Keppler, DO; Koch, HK; Lattke, H; Lesch, R, 1979
)
0.26
"A wide dose-response curve and the inhibitory effect on mitogenicity of specific antitoxin suggest that polyclonal lymphocyte activation by staphylococcal enterotoxin requires direct interaction of toxin with lymphocyte receptors of low avidity for the protein."( Evidence for cell-receptor activity in lymphocyte stimulation by staphylococcal enterotoxin.
Leatherman, DL; Metzger, JF; Warren, JR, 1975
)
0.25
" Injection of protein or glycoprotein precursors into one Rc produced heavy labeling of both Rcs including their processes; a slight labeling of other ganglion compartments was only found after increasing the dosage of the amino acids glycine and leucine."( Transfer of radioactive material between electrically coupled neurons of the leech central nervous system.
Kreutzberg, GW; Rieske, E; Schubert, P, 1975
)
0.25
" The increased fucosylation of these glycoproteins showed a distinct dose-response relationship."( Increased fucosylation of high-molecular-weight glycoproteins accompanies retinoic-acid-induced differentiation of F-9 embryonal carcinoma cells.
Amos, B; Lotan, D; Lotan, R, 1990
)
0.28
" Such a gene dosage effect of GAL80 was further pronounced if sucrose, a sugar causing catabolite repression, was added to the growth medium."( Regulation of expression of the galactose gene cluster in Saccharomyces cerevisiae. II. The isolation and dosage effect of the regulatory gene GAL80.
Fukasawa, T; Hashimoto, H; Matsuzaki, Y; Nogi, Y; Shimada, H, 1984
)
0.27
" The sialic acid/fucose ratio in sputum correlated significantly with the slope of the dose-response curve during inhalation challenge, and with the %FEV1 after beta-agonist inhalation."( [Relation between the sialic acid/fucose ratio in airway secretions and the degree of airway remodeling in bronchial asthma--reversibility of airflow limitation by beta-agonists and airway remodeling in bronchial asthma].
Inoue, H; Kobayashi, H; Tomichi, N; Yamauchi, K, 1996
)
0.29
" It was found that only the 4-mumol dosage was followed by PAR disruption."( 2-Deoxy-D-galactose effects on passive avoidance memorization in the rat.
Baldi, E; Bucherelli, C; Lorenzini, CG; Sacchetti, B; Tassoni, G, 1997
)
0.3
" To gain insight into the terminal saccharides required to form a functional sperm-binding ligand, dose-response curves were generated for a series of related tri- and tetrasaccharides to evaluate their relative effectiveness to competitively inhibit the in vitro binding of murine sperm to zona pellucida-enclosed eggs."( Murine sperm-zona binding, a fucosyl residue is required for a high affinity sperm-binding ligand. A second site on sperm binds a nonfucosylated, beta-galactosyl-capped oligosaccharide.
Hokke, CH; Johnston, DS; Joziasse, DH; Shaper, JH; Van den Eijnden, DH; Wright, WW, 1998
)
0.3
" Dose-response analyses demonstrated that these glycans are potent inhibitors (IC(50) approximately 180 nM), which at saturation, reduced Alexa(568)-ZP3 binding by approximately 70%."( Lewis X-containing glycans are specific and potent competitive inhibitors of the binding of ZP3 to complementary sites on capacitated, acrosome-intact mouse sperm.
Hanna, WF; Kerr, CL; Shaper, JH; Wright, WW, 2004
)
0.32
" Dose-response analyses in mice then showed that a sample of the human IgG1 version of 2C11 Ab in which 40% of the Fc glycans in the population of Ab molecules were fucosylated was 3-5 times more potent than a sample with 90% of its Fc glycans fucosylated."( Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
Cai, A; Capocasale, R; McCarthy, S; Naso, M; Radewonuk, J; Raju, TS; Scallon, B, 2007
)
0.34
", FSAR and FVES, decreased the proliferation of the melanoma cells in a dose-response fashion, with FSAR being more potent at lower dosages, and FVES being relatively more anti-proliferative than FSAR at higher dosages."( Fucose-containing sulfated polysaccharides from brown seaweeds inhibit proliferation of melanoma cells and induce apoptosis by activation of caspase-3 in vitro.
Ale, MT; Maruyama, H; Meyer, AS; Mikkelsen, JD; Tamauchi, H, 2011
)
0.37
" Based on EC 50 values derived from dose-response curves, our results indicate that the amount of afucosylated glycan in antibody samples correlate with both FcγRIIIa binding activity and ADCC activity in a linear fashion."( Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
Chung, S; Fong, C; Gao, X; Lau, W; Lin, L; Qiu, ZJ; Quarmby, V; Reed, C; Shen, A; Song, A; Vanderlaan, M; Ying, Y,
)
0.13
" This ADCC bridging method is simple, offers the ease of use of a standard ELISA, and shows reproducible dose-response curves in the concentration range of 50-1000 ng/mL."( Development of an ELISA based bridging assay as a surrogate measure of ADCC.
Gazzano-Santoro, H; Miller, AS; Tejada, ML, 2012
)
0.38
" Thus, NEC-stressed (N-S) rat pups were orally dosed with breastmilk components lysozyme (N-S-LYS) or docosahexaenoic acid (N-S-DHA)."( Impact of Developmental Age, Necrotizing Enterocolitis Associated Stress, and Oral Therapeutic Intervention on Mucus Barrier Properties.
Carlson, TL; Carrier, RL; Claud, EC; Lock, JY; Lu, J; Yu, Y, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
deoxygalactose
L-fucoseAny form of fucose having L configuration.
fucopyranose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (14)

PathwayProteinsCompounds
Fructose and Mannose Degradation1830
Fructosuria1830
Fructose Intolerance, Hereditary1830
Metabolism of proteins1058144
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Transport to the Golgi and subsequent modification8518
N-glycan antennae elongation in the medial/trans-Golgi2013
Reactions specific to the complex N-glycan synthesis pathway1010
GDP-L-fucose biosynthesis II (from L-fucose)08
Fructose and Mannose metabolism ( Fructose and Mannose metabolism )2527
plant arabinogalactan type II degradation04
xyloglucan degradation II (exoglucanase)112
GDP-L-fucose biosynthesis II (from L-fucose)09
xyloglucan degradation I (endoglucanase)04

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fucose-binding lectin PA-IILPseudomonas aeruginosa PAO1IC50 (µMol)2.13000.91002.13002.7400AID1526585; AID1526586; AID1540365
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
regulation of T cell proliferationCD209 antigenHomo sapiens (human)
adaptive immune responseCD209 antigenHomo sapiens (human)
endocytosisCD209 antigenHomo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesCD209 antigenHomo sapiens (human)
leukocyte cell-cell adhesionCD209 antigenHomo sapiens (human)
cell-cell recognitionCD209 antigenHomo sapiens (human)
virion attachment to host cellCD209 antigenHomo sapiens (human)
viral genome replicationCD209 antigenHomo sapiens (human)
antigen processing and presentationCD209 antigenHomo sapiens (human)
intracellular signal transductionCD209 antigenHomo sapiens (human)
positive regulation of T cell proliferationCD209 antigenHomo sapiens (human)
innate immune responseCD209 antigenHomo sapiens (human)
symbiont entry into host cellCD209 antigenHomo sapiens (human)
peptide antigen transportCD209 antigenHomo sapiens (human)
intracellular transport of virusCD209 antigenHomo sapiens (human)
B cell adhesionCD209 antigenHomo sapiens (human)
positive regulation of viral life cycleCD209 antigenHomo sapiens (human)
immune responseCD209 antigenHomo sapiens (human)
biological process involved in interspecies interaction between organismsCD209 antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
virus receptor activityCD209 antigenHomo sapiens (human)
protein bindingCD209 antigenHomo sapiens (human)
mannose bindingCD209 antigenHomo sapiens (human)
carbohydrate bindingCD209 antigenHomo sapiens (human)
peptide antigen bindingCD209 antigenHomo sapiens (human)
virion bindingCD209 antigenHomo sapiens (human)
metal ion bindingCD209 antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionCD209 antigenHomo sapiens (human)
cytoplasmCD209 antigenHomo sapiens (human)
plasma membraneCD209 antigenHomo sapiens (human)
external side of plasma membraneCD209 antigenHomo sapiens (human)
cell surfaceCD209 antigenHomo sapiens (human)
membraneCD209 antigenHomo sapiens (human)
host cellCD209 antigenHomo sapiens (human)
external side of plasma membraneCD209 antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID381597Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381595Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutinination relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID1072562Displacement of [125I]-Man30-BSA from DC-SIGN receptor carbohydrate recognition domain (unknown origin) after 2 hrs by gamma-counting analysis2014European journal of medicinal chemistry, Mar-21, Volume: 75Monovalent mannose-based DC-SIGN antagonists: targeting the hydrophobic groove of the receptor.
AID202218Percentage incorporation of 5 mM 6-F-galactose into macromolecule of human mammary tumor cells was measured in the presence of radiolabeled [3H]galactose, as cpm/ug of protein1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Halogenated L-fucose and D-galactose analogues: synthesis and metabolic effects.
AID381592Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutinination2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID1526586Competitive inhibition of N-(fluorescein-5-yl)-N'-(alpha-L-fucopyranosyl ethylen)-thiocarbamide binding to Pseudomonas aeruginosa PA14 LecB after 8 to 22 hrs by fluorescence polarization assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Anti-biofilm Agents against
AID381594Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutinination2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID202220Percentage uptake of 5 mM 6-F-galactose into macromolecule of human mammary tumor cells was measured in the presence of radiolabeled [3H]galactose, as cpm/ug of protein1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Halogenated L-fucose and D-galactose analogues: synthesis and metabolic effects.
AID1072561Displacement of biotinylated HIV1 gp120 from DC-SIGN receptor carbohydrate recognition domain (unknown origin) after 2 hrs by solid-phase competitive displacement assay2014European journal of medicinal chemistry, Mar-21, Volume: 75Monovalent mannose-based DC-SIGN antagonists: targeting the hydrophobic groove of the receptor.
AID1540365Inhibition of Pseudomonas aeruginosa LecB by fluorescence polarization assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Glycocluster Tetrahydroxamic Acids Exhibiting Unprecedented Inhibition of
AID1681525Inhibition of Pseudomonas aeruginosa PAO1 LecB expressed in Escherichia coli BL21(DE3) cells incubated for 4 to 8 hrs by (N-(fluorescein-5-yl)-N'-(alpha-L-fucopyranosyl ethylene)thiocarbamide) reporter based fluorescence polarization assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Directing Drugs to Bugs: Antibiotic-Carbohydrate Conjugates Targeting Biofilm-Associated Lectins of
AID30427Compound was tested for inhibition of Human acrosin by aldohexoses1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID381593Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutinination relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381596Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID1526585Inhibition of Pseudomonas aeruginosa PAO1 LecB after 6 hrs by fluorescence polarization assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Anti-biofilm Agents against
AID1681524Inhibition of Pseudomonas aeruginosa PA14 LecB expressed in Escherichia coli BL21(DE3) cells incubated for 4 to 8 hrs by (N-(fluorescein-5-yl)-N'-(alpha-L-fucopyranosyl ethylene)thiocarbamide) reporter based fluorescence polarization assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Directing Drugs to Bugs: Antibiotic-Carbohydrate Conjugates Targeting Biofilm-Associated Lectins of
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,415)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902728 (50.38)18.7374
1990's675 (12.47)18.2507
2000's731 (13.50)29.6817
2010's903 (16.68)24.3611
2020's378 (6.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials26 (0.47%)5.53%
Reviews0 (0.00%)6.00%
Reviews213 (3.81%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies48 (0.86%)4.05%
Observational0 (0.00%)0.25%
Observational1 (0.02%)0.25%
Other8 (100.00%)84.16%
Other5,296 (94.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]